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VUF10166 (2-chloro-3-(4-methyl piperazin-1-yl)quinoxaline) is a ligand that binds with high afﬁnity to
5-HT3 receptors. Here we synthesise [3H]VUF10166 and characterise its binding properties at 5-HT3A and
5-HT3AB receptors. At 5-HT3A receptors [3H]VUF10166 displayed saturable binding with a Kd of 0.18 nM.
Kinetic measurements gave monophasic association (6.25  107 M1 min1) and dissociation
(0.01 min1) rates that yielded a similar Kd value (0.16 nM). At 5-HT3AB receptors two association
(6.15  107, 7.23 M1 min1) and dissociation (0.024, 0.162 min1) rates were seen, yielding Kd values
(0.38 nM and 22 nM) that were consistent with values obtained in saturation (Kd ¼ 0.74 nM) and
competition (Ki ¼ 37 nM) binding experiments respectively. At both receptor types, speciﬁc binding was
inhibited by classical 5-HT3 receptor-selective orthosteric ligands (5-HT, allosetron, d-tubocurarine,
granisetron, mCPBG, MDL72222, quipazine), but not by non-competitive antagonists (bilobalide, gink-
golide B, picrotoxin) or competitive ligands of other Cys-loop receptors (ACh, bicuculline, glycine,
gabazine). To explore VUF10166 ligandereceptor interactions we used in silico modelling and docking,
and tested the predictions using site directed mutagenesis. The data suggest that VUF10166 adopts a
similar orientation to 5-HT3 receptor agonists bound in AChBP (varenicline) and 5HTBP (5-HT) crystal
structures.
© 2014 Published by Elsevier Ltd.1. Introduction
5-HT3 receptors are transmembrane ligand-gated ion-channels
that are responsible for fast synaptic neurotransmission in the
central and peripheral nervous systems. They are composed of ﬁve
subunits, each of which contains an extracellular, a transmembrane
and an intracellular domain (Thompson et al., 2008a; Miller and
Smart, 2012). In vivo 5-HT3 receptor activation can result in
nausea and vomiting, and for over three decades competitive an-
tagonists of these receptors have been used to alleviate these
symptoms arising from cancer therapy and general anaesthetics.
There is also a limited use of antagonists for treating irritable bowelCh, nicotinic acetylcholine;
yonic kidney; AChBP, acetyl-
diﬁed to resemble the 5-HT3R
zin-1-yl)quinoxaline.
; fax: þ44 (0) 1223 333345.syndrome and pre-clinical interest in the use of partial agonists for
the same disorder (Thompson and Lummis, 2007; Walstab et al.,
2010; Thompson, 2013).
There are currently ﬁve 5-HT3 receptor subunits (5-HT3Ae5-
HT3E), with further complexity arising from splice variants and
species differences (Walstab et al., 2010). 5-HT3A subunits can form
homomeric receptors, but the subunits 5-HT3Be5-HT3E must
combine with 5-HT3A subunits to function. The functional prop-
erties of these receptor subtypes have been reported by several
groups, but to date only the pharmacologies of 5-HT3A and 5-
HT3AB receptors have been studied in detail (Holbrook et al.,
2009; Walstab et al., 2010; Thompson et al., 2013; Thompson and
Lummis, 2013). Until recently only pore-blocking antagonists
were known to have different properties at 5-HT3A and 5-HT3AB
receptors, and these differences could be attributed to the varying
pore-lining amino acids of the 5-HT3A and 5-HT3B subunits
(Thompson and Lummis, 2013). However, the utility of these
compounds is limited as they tend to be of low afﬁnity (mM range)
Fig. 1. Radioligand binding at 5-HT3A receptors. (a) Representative binding curves for 5-HT3A receptors. Inset competition binding of unlabelled VUF10166 with [3H]granisetron. (b)
Association of [3H]VUF10166 was ﬁt with a mono-exponential function to yield kobs. (c) Linear regression was used to ﬁt kobs against the radioligand concentration, yielding the kon
(slope) and koff (intercept at y ¼ 0) values in Table 1. (d) Dissociation of [3H]VUF10166 was best ﬁt with a single exponential (koff ¼ 0.011 ± 0.001 min1, n ¼ 4). (e) For [3H]
granisetron, association was also best ﬁt with mono-exponential functions that were used to plot kobs against the concentration to yield the kon and koff values in Table 1. (f)
Dissociation of [3H]granisetron (koff ¼ 0.011 ± 0.001 min1, n ¼ 5).
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descriptions of two compounds with other sites of action that
discriminate between 5-HT3A and 5-HT3AB receptor subtypes. One
of these, topotecan, primarily an anticancer drug, was found to
inhibit 5-HT3A and potentiate 5-HT3AB receptors, although this
compound also has a relatively low (mM) potency (Nakamura et al.,
2013). The second compound is VUF10166 (2-chloro-3-(4-
methylpiperazin-1-yl)quinoxaline), which is highly potent, with
an afﬁnity at 5-HT3A receptors (pKi ~ 10) that is ~100-fold greater
than at 5-HT3AB receptors (Thompson et al., 2012). We previously
showed that VUF10166 binds to the orthosteric binding site of both
5-HT3A and 5-HT3AB receptors (formed at the interface of two 5-
HT3A subunits, AþA) and that a second, allosteric, binding site(AþB) in the 5-HT3AB receptor was responsible for causing li-
gands at the AþA binding site to dissociate more rapidly.
Here we perform a detailed characterisation of VUF10166
binding to 5-HT3A and 5-HT3AB receptors with a radiolabelled
version of this compound and use mutagenesis to explore the
residues that interact with VUF10166 at the AþA binding site.
2. Experimental procedures
2.1. Synthesis of [3H]VUF10166
60 ml [3H]methyl nosylate (0.7 GBq/ml, 19 mCi/ml) in hexane/ethyl acetate (10/2
v/v) was injected into a closed reaction screwcap reaction vessel and the solvent
evaporated under argon at 60 C. 2-chloro-3-(piperazin-1-yl)quinoxaline hydro-
chloride (7.2 mg, 0.025 mmol) in dry DMF (150 ml) and DIPEA (30.7 mL, 0.176 mmol)
Table 1
Binding parameters for VUF10166 and BRL43694.
Receptor kon
(M1 min1)
koff
(min1)
Kd(nM)
(kon/koff)
Kd (nM)
saturation
Ki (nM)
competitiona
VUF10166
5-HT3A 6.25  107 0.010 0.16 0.18 ± 0.04 (11) 0.24 ± 0.11 (12)
5-HT3AB b6.15  107
b7.23  106
0.024
0.162
0.38
22.4
e 36.7 ± 12.4 (12)
BRL43694
5-HT3A 5.90  107 0.064 1.08 0.68 ± 0.05 (12) e
5-HT3AB 1.20  108 0.074 0.62 0.74 ± 0.10 (4) e
a Competition binding was performed with [3H]BRL43694 and unlabelled
VUF10166. kon and koff were calculated from plots of kobs versus ligand concentra-
tion (Figs. 1 and 5). e not determined.
b Not signiﬁcantly different to 5-HT3A (p > 0.05, Student's t-test).
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semi-prep HPLC eluent and subjected to semi-preparative HPLC puriﬁcation, using a
Reprosphere C18-DE 5 mM, 50*8 mm column as stationary phase (Dr. Maisch,
Ammerbuch-Entringen, Germany) and acetonitrile/water 75/25 (v/v) with 0.1%
diisopropylethylamine as eluent at a ﬂow of 3 ml min1, with UV monitoring at
254 nm (Jasco UV-1575, Jasco, de Meern, Netherlands). 30 s fractions were collected,
5 ml of each added to 5 ml scintillation ﬂuid, and counted for 1 min in a beta well
counter (Rackbeta 1219 LSC, LKB-Wallac, Netherlands). Fractions containing 2-
chloro-3-(4-[3H]methylpiperazin-1-yl)quinoxaline were diluted with 45 ml sterile
water and passed over a preconditioned Waters tC18 plus Sep-Pak, washed with
20 ml of water, and the product obtained by elution with 1.5 ml ethanol; 35 MBq
(83% radiochemical yield) of [3H]VUF10166 was obtained. The speciﬁc activity of the
product was 3.13 TBq/mmol (84.5 Ci/mmol) and the radiochemical purity was >98%,
as determined by HPLC with a Platinum C18 100a, 5 mM 250*4.6 mm column (Grace
Alltech, Breda, Netherlands) as stationary phase and acetonitrile/10 mM ammo-
niumdihydrogen phosphate buffer pH 2.5 50/50 (v/v) as eluent at a ﬂow of
1 ml min1, with UV monitoring at 254 nm (Jasco UV-1575) and radioactivity
monitoring (Lablogic b-RAM model 4, Metorix, Goedereede, Netherlands).
2.2. Site-directed mutagenesis
Mutagenesis was performed using the QuikChange method (Agilent Technolo-
gies Inc., California, USA) on human 5-HT3A cDNA (accession number: P46098)
cloned into pcDNA3.1 (Invitrogen, Paisley, UK). Cysteine residues were substituted
for amino acids throughout each of the binding loops AeE (Fig. 1). To facilitate
comparisons with previous work, we use the numbering of the equivalent residues
in the mouse 5-HT3A subunit; for human numbering 5 should be subtracted from
each residue number.
2.3. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were maintained as monolayer cul-
tures grown on 90 mm tissue culture plates in DMEM:F12 (Dulbecco's Modiﬁed
Eagle Medium/Nutrient Mix F12 (1:1)) with GlutaMAX™ I media (Gibco BRL, Paisley,
U.K.) containing 10% foetal calf serum (HyClone, Thermo Scientiﬁc, Cramlington,
UK), at 37 C and 7% CO2, with a humidiﬁed atmosphere. Cells were transfected
using polyethyleneimine (PEI, Polysciences Inc., Eppelheim, Germany), and incu-
bated for 2e3 days before harvesting.
2.4. Radioligand binding
Transfected HEK 293 cells were washed twice with phosphate buffered saline
(PBS) at room temperature, scraped into 1 ml of ice-cold HEPES buffer (10 mM, pH
7.4), homogenised and frozen. After thawing, they were washed with HEPES buffer,
resuspended, and 50 mg of cell suspension incubated in 0.5 ml HEPES buffer and the
relevant concentration of radioligand at 0 C. Non-speciﬁc binding was determined
using 2 mM quipazine. Equilibrium reactions were incubated for at least 3 h for [3H]
granisetron (63.5 Ci/mmol, PerkinElmer, Boston, Massachusetts, USA) and 48 h for
[3H]VUF10166. Incubations were terminated by vacuum ﬁltration onto GF/B ﬁlters
pre-soaked in 0.3% polyethyleneimine, followed by three rapid washes with 3.5 ml
ice cold buffer. Radioactivity was determined by scintillation in Ecoscint A (National
Diagnostics, Atlanta, Georgia) using a Beckman LS6000SC (Fullerton, California,
USA). Each method was performed on at least three independent cell samples on at
least three separate days.
2.4.1. Saturation binding
To construct saturation binding curves a range of [3H]granisetron (0.25e2 nM)
or [3H]VUF10166 (0.04e50 nM) concentrations were used according to the condi-
tions described above. Final counts were monitored to ensure that binding never
exceeded 10% of the added concentrations of radioligands.
2.4.2. Competition binding
Afﬁnities of unlabelled Cys-loop receptor ligands were determined by adding a
range (2 pMe2 mM) of concentrations to samples containing 0.2 nM [3H]VUF10166
or 0.7 nM [3H]granisetron for 5-HT3A receptors, and 0.6 nM [3H]VUF10166 or 0.7 nM
[3H]granisetron for 5-HT3AB receptors.
2.4.3. Kinetic measurements
To determine the association rate (kon), the observed association rate (kobs) was
measured for a range of radioligand concentrations. The experiment was started
(t ¼ 0) by the addition of radioligand to 500 ml cell suspension in HEPES buffer and
harvested at varying time points to construct association curves.
Dissociation was measured by allowing each radioligand to reach equilibrium
according to the times described above and then adding a ﬁnal concentration of
2 mM quipazine (~Kd  106) to each tube for varying time periods.
2.5. Data analysis
All datawere analysed using GraphPad Prism 4.03. Individual saturation binding
experiments were ﬁtted to Equ (1), and the values averaged to obtain mean ± sem:y ¼ Bmax 

L

Kd
Kd þ ½L
(1)
where Bmax is maximum binding at equilibrium, Kd is the equilibrium dissociation
constant and [L] is the free concentration of radioligand. Individual competition
binding experiments were analysed by iterative curve ﬁtting using the following
equation and the values averaged to obtain the mean ± sem:
y ¼ Bmin þ
Bmax  Bmin
1þ 10 L½ $log IC50 (2)
where Bmin is the non-speciﬁc binding, Bmax is the maximum speciﬁc binding, [L] is
the concentration of competing ligand and IC50 is the concentration of competing
ligand that blocks half of the speciﬁc bound radioligand.
A simple bimolecular binding scheme for receptor and ligand can be represented
as:
Lþ R#kon
koff
LR (3)
where L is the free ligand concentration, R receptor concentration, LR bound receptor
concentration, and kon and koff microscopic association and dissociation rate con-
stants. In a simple scheme such as this, the equilibrium dissociation constant (Kd) is
equal to the ratio of dissociation to association rate constants, such that:
Kd ¼
koff
kon
(4)
Dissociation data were ﬁtted to either a single or double exponential decay to
yield koff. Association datawere ﬁtted to a single exponential association to calculate
kobs. If kobs is plotted against the radioligand concentration, according to a simple
model, the slope of this plot equals the association constant (kon) and the y-intercept
of this line (at x ¼ 0) is the dissociation constant (koff). kon can also be calculated as
described by Hill (Hill, 1909), where koff is predetermined from radioligand disso-
ciation rate experiments.
kon ¼ kobs  koff½L (5)
2.6. Homology modelling
The protein sequence of the human 5-HT3A subunit (accession number;
P46098) was aligned with a tropisetron bound AChBP template (PDB ID; 2WNC)
using FUGUE. Using Modeller 9.9, ﬁve homology models were generated using
default parameters and the best model selected using Ramachandran plot analysis.
For the ligand, the protonated form of VUF10166 was constructed in Chem3D Ultra
7.0 (CambridgeSoft, Cambridge, UK). The binding site was deﬁned as being within
5 Å of the a-carbon of W183, a residue critical in the binding of other 5-HT3
competitive ligands. VUF10166 was docked into this site using the GOLD docking
program (version 3.0, The Cambridge Crystallographic Data Centre, Cambridge, UK)
with the GOLDScore function and default settings. Ten docking poses were gener-
ated for each of the ﬁve homology models and the poses visualised with PyMol v1.3.
3. Results
3.1. [3H]VUF10166 binding at 5-HT3A receptors
[3H]VUF10166 showed high afﬁnity saturable binding at 5-HT3A
receptors with low levels (<5%) of non-speciﬁc binding. The Kd
value was similar to the Ki value from competition of unlabelled
A.J. Thompson et al. / Neuropharmacology 86 (2014) 378e388 381VUF10166 with [3H]granisetron (Fig. 1a, Table 1). Bmax values for
[3H]VUF10166 (2229 ± 158 fmol/mg, n ¼ 6) were comparable to
those with [3H]granisetron (2263 ± 101, n ¼ 6) on paired samples,
suggesting that both ligands bind to the same receptor population.3.2. VUF10166 kinetic parameters at 5-HT3A receptors
Association curves for [3H]VUF10166 were best ﬁt with a single
exponential function (Fig. 1b), and the resultant rates (kobs) plotted
against ligand concentration to yield kon and koff (Fig. 1c, Table 1).
The value for kon was similar to values determined directly from
kobs values using Equ (5) (8.24  107 M min1). Dissociation of [3H]
VUF10166 in the presence of excess cold quipazine was also
monophasic (Fig. 1d), with koff values that were similar to those
determined from plots of kobs against ligand concentration
(Table 1). Kd values calculated from these kinetic measurements
(Equ (4)) were similar to those derived from the saturation and
competition binding (Table 1). These results indicate [3H]
VUF101666 binding can be best described by a simple bi-molecular
binding scheme.3.3. Speciﬁcity of binding
A range of competitive and non-competitive ligands of 5-HT3
and related Cys-loop receptors were tested for their ability to
compete with [3H]VUF10166 binding (Table 2). All tested 5-HT3
receptor competitive ligands (agonists and antagonists) displaced
speciﬁc [3H]VUF10166 binding. Binding was unaffected by the non-
competitive ligands bilobalide, ginkgolide and picrotoxin, or the
majority of competitive ligands of other Cys-loop receptors. Ex-
ceptions were strychnine (glycine receptor antagonist) and nicotine
(nACh receptor agonist); these were later shown to also compete
with [3H]granisetron.
Previously we showed that unlabelled VUF10166 does not
compete with [3H]epibatidine at a7 nACh receptors (the closest
pharmacologically related receptor) (Thompson et al., 2012). Here
we performed saturation binding experiments on a7 nACh re-
ceptors using [3H]VUF10166 which revealed no speciﬁc saturable
binding (data not shown).
These results show that classical 5-HT3 receptor competitive
antagonists compete with [3H]VUF10166, showing it binds at the
orthosteric site.Table 2
Competition of Cys-loop receptor ligands with [3H]VUF10166.
Compound pIC50
5-HT3A 5-HT3AB
Allosetron 11.14 ± 0.01 (4) 11.15 ± 0.10 (4)
Quipazine 8.84 ± 0.03 (4) 8.60 ± 0.75 (5)
MDL72222 12.90 ± 0.01 (3) 13.23 ± 0.11(1)
mCPBG 7.49 ± 0.06 (4) 6.07 ± 0.20 (5)
Granisetron 10.48 ± 0.08 (4) 10.35 ± 0.10 (3)
d-Tubocurarine 5.41 ± 0.06 (4) 5.44 ± 0.30 (4)
5-HT 4.54 ± 0.07 (3) 4.49 ± 0.09 (3)
ACh NB (4) NB (3)
GABA NB (4) NB (3)
Glycine NB (4) NB (3)
Gabazine NB (4) NB (3)
Bicuculline NB (5) NB (3)
Strychnine 5.83 ± 0.09 (4) 6.26 ± 0.01 (2)
Picrotoxin NB (3) NB (3)
Bilobalide NB (3) NB (2)
Ginkgolide NB (3) NB (3)
Nicotine 6.81 ± 0.23 (4) 6.76 ± 0.09 (2)3.4. Granisetron binding at 5-HT3A receptors
To compare [3H]VUF10166 with a well-established 5-HT3 re-
ceptor competitive ligand, experiments were also conducted using
[3H]granisetron. As expected, [3H]granisetron showed high afﬁnity
binding at 5-HT3A receptors (Table 1). Competition binding with a
range of known 5-HT3 receptor agonists and antagonists gave Ki
values similar to those determined using competition with [3H]
VUF10166 (Table 3) and to those published elsewhere (Brady et al.,
2001). Similar to [3H]VUF10166, nicotine and strychnine competed
with [3H]granisetron.
[3H]granisetron association rates were best ﬁt with a mono-
phasic curve. kobs increased with free ligand concentration and a
straight line was ﬁtted (Fig. 1e) to yield the kon and koff values in
Table 1. Kd values calculated from these kinetic measurements (Equ
(4)) were in agreement with afﬁnities calculated from our satura-
tion binding studies (Table 1). Dissociation was also monophasic
and the rate agreed well with that from our kobs versus concen-
tration plots described above (Fig. 1f, Table 1).
These observations show that using a well-established radio-
labelled 5-HT3 receptor antagonist ([3H]granisetron) we are able to
accurately reproduce the binding characteristics reported else-
where and, similar to [3H]VUF10166, they are consistent with a
simple bi-molecular binding scheme.
3.5. Homology modelling & docking
To gain insights into the residues that potentially interact with
VUF10166 at the orthosteric site (AþA interface), ﬁve 5-HT3A
receptor homology models were generated and in silico docking of
VUF10166 performed on each one (Fig. 2). A total of 50 docked
poses were generated and for each of these the amino acids within
5 Å of VUF10166 were identiﬁed (Table 4). 26% of residues were
common to all models, comparable to a previous docking study
with granisetron, where 31% of residues were common to all of the
predicted binding orientations (Thompson et al., 2005). A selection
of these residues were chosen for mutagenesis based upon the
following criteria, 1) side chains accessible to the ligand, 2) residues
known to interact with other 5-HT3 ligands or, 3) residues present
in a limited number of docked poses to provide support for speciﬁc
orientations. Of the 39 amino acids identiﬁed, 23 were mutated to
cysteine (Fig. 3); cysteine substitution of these residues was chosen
as all of the Cys mutants have been previously shown to express on
the cell-surface, and the residue positions have been similarly used
for the study of our radioligand standard, [3H]granisetron
(Thompson et al., 2005, 2011).
3.6. Effects of mutations
The binding afﬁnity of [3H]VUF10166 at each of the mutant re-
ceptors is shown in Table 5, and their locations in Fig. 4. Changing 3
of the 23 residues resulted in no signiﬁcant change in afﬁnity,Table 3
Competition of Cys-loop receptor ligands with [3H]BRL43694.
Compound pIC50
5-HT3A 5-HT3AB
Quipazine 8.60 ± 0.02 (5) 8.12 ± 0.18 (5)
MDL72222 8.05 ± 0.09 (3) 7.96 ± 0.15 (3)
mCPBG 6.88 ± 0.13 (7) 6.64 ± 0.12 (5)
Granisetron 9.12 ± 0.05 (7) 9.14 ± 0.09 (4)
d-Tubocurarine 4.61 ± 0.17 (3) 4.29 ± 0.47 (3)
5-HT 6.38 ± 0.35 (6) 5.64 ± 0.45 (5)
Nicotine 6.01 ± 0.61 (3) 6.56 ± 0.12 (3)
Strychnine 4.30 ± 0.09 (3) 4.85 ± 0.19 (3)
Fig. 2. Predicted binding clusters for VUF10166 docked into ﬁve different homology models of the 5-HT3 receptor AþA binding site. All 10 predicted ligand poses are shown for
each model. The 5-HT3 receptor residues within 5 Å of VUF10166 in each of the docked poses are shown in Table 4.
A.J. Thompson et al. / Neuropharmacology 86 (2014) 378e388382suggesting these residues do not play a role in ligand binding (I71,
K112, S114). For the remaining 20mutants therewere differences in
the binding afﬁnities when compared to wild type receptors,
indicating that these residuesmay have a role in VUF10166 binding.
For 9 of these residues [3H]VUF10166 had reduced afﬁnities (R92,
L126, N128, I139, R145, Q151, Y153, H185, F226) and for 11 no
saturable binding (Kd > 10 nM)was detected (R58,W90, E129, Y141,
Y143, T179, T181, W183, H185, D189, Y234, E236). All these mutant
receptors have been previously shown to express in oocytes
(Thompson et al., 2012).These data show that [3H]VUF10166 binds to the orthosteric site
and are consistent with our ﬁndings that [3H]VUF10166 competes
with other 5-HT3 receptor competitive ligands.
3.7. VUF10166 binding at 5-HT3AB receptors
VUF10166 was previously shown to discriminate between 5-
HT3 receptors subtypes (Thompson et al., 2012) and so binding
properties of the new radioligand were also tested at 5-HT3AB
receptors. [3H]VUF10166 showed high afﬁnity binding at 5-
Table 4
Residues within 5 Å of docked VUF10166 in 5 different homology models of the 5-HT3A receptor binding site.
A.J. Thompson et al. / Neuropharmacology 86 (2014) 378e388 383HT3AB receptors, but unlike at 5-HT3A receptors, it was complex
and could not be ﬁt with a single site model (Fig. 5a). Dissocia-
tion of [3H]VUF10166 at these receptors was best ﬁt with a
double exponential curve, which contained both a fast and a slow
component; the latter was not signiﬁcantly different (p < 0.05) to
the single rate measured at 5-HT3A receptors (Fig. 5b, Table 1).
Association curves were monophasic (Fig. 5c), but when kobs was
plotted against radioligand concentration, the data were also best
approximated by a two site ﬁt (Fig. 5d, Table 1). At concentrationsFig. 3. An amino acid sequence alignment showing the positions of residues mutated in this
lines above the text. Positions of b-sheets are shown by grey lines beneath the text. Numberin
(Celie et al., 2004). The proteins are the human 5-HT3A subunit (P46098) and Lymnaea staof [3H]VUF10166 < 3 nM the koff and kon values were similar to 5-
HT3A receptors; below 3 nM, average kon values determined from
kobs (Equ (5)) were also similar to 5-HT3A receptors
(8.77  107 M min1). At concentrations >3 nM, koff and kon had
slower rates that yielded a Kd (22.4 nM; Equ (4)) close to the
value from competition binding (36.7 nM; Table 1). Competition
binding with a range of ligands was performed using 0.6 nM [3H]
VUF10166 and Ki values were similar to values at 5-HT3A re-
ceptors (Table 2).study (white text, grey boxes). The six recognised binding loops are indicated by black
g of residues and structural features are taken from the AChBP protein crystal structure
gnalis AChBP (58154).
Table 5
Saturation binding of [3H]VUF10166 at 5-HT3A receptor mutants.
A.J. Thompson et al. / Neuropharmacology 86 (2014) 378e388384These results show that [3H]VUF10166 has different binding
properties at 5-HT3A and 5-HT3AB receptors. In the latter effects are
complex and some only become apparent at higher concentrations
of [3H]VUF10166.3.8. Granisetron binding at 5-HT3AB receptors
Unlike [3H]VUF10166, [3H]granisetron saturation binding at 5-
HT3AB receptors yielded Kd values that were the same as those at
5-HT3A receptors, as reported elsewhere (Table 1) (Brady et al.,
2001). Association (Fig. 5e), dissociation (Fig. 5f) and Ki values
from competition binding (Table 3) were also the same as those at
5-HT3A receptors.
These results show that the binding properties of [3H]granise-
tron are the same at 5-HT3A and 5-HT3AB receptors unlike those of
[3H]VUF10166.4. Discussion
[3H]VUF10166 binds speciﬁcally and with high afﬁnity to 5-
HT3A and 5-HT3AB receptors, with evidence of a second, lower
afﬁnity, binding site in 5-HT3AB receptors. The effects of this second
site are apparent at concentrations of [3H]VUF10166 > 3 nM, and
are consistent with previous work that identiﬁed an additional
allosteric binding site for unlabelled VUF10166 at the AþB inter-
face (Thompson et al., 2012). Docking of this competitive ligand
into the orthosteric (AþA) binding site, combined with data from
mutagenesis, suggest that VUF10166 is oriented with its quinoxa-
line rings close to W183 and its basic nitrogen extended towards
loop E. Individual residues, many of which have been previously
shown to be important in studies of other 5-HT3 receptor ligands
(including d-tubocurarine, granisetron, lerisetron, meta-chlor-
ophenylbiguanide and tropisetron) are also important for
VUF10166 binding (Hope et al., 1999; Mochizuki et al., 1999;
Fig. 4. Binding site residues mutated in this study, colour coded according to the change in Kd. A large number of residues that abolish binding (afﬁnity > 10 nM) are clustered
around loop B, with further signiﬁcant changes in loop D (W90) and loop E (Y141 & Y143). Not all changes are likely to result from ligand interactions, such as the effect of D189C
which is consistent with it maintaining the hydrogen bond network in the tight loop at the C-terminal end of loop B. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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are discussed in more detail below.
4.1. The role of loop A residues
VUF10166 binding was abolished by Cys substitution of E129,
slightly modiﬁed by L126C (~4 fold change in Kd) and not altered by
N128C. E129 was previously identiﬁed as an important 5-HT3 re-
ceptor binding residue and may form a hydrogen bond with bound
ligand, which is consistent with our data (Price et al., 2008).
However, data from 5HTBP (a modiﬁed AChBP with high afﬁnity
binding for 5-HT3 receptor ligands) suggest that E129 may
hydrogen bond with the side chain of T179 (Kesters et al., 2013),
and therefore might have primarily a structural role. L126 may also
have a structural role but is less important as the effects of altering
this residue were small, while N128 has been shown to play a role
in gating but not binding (Price et al., 2008; Kesters et al., 2013).
4.2. The role of loop B residues
Loop B has been previously identiﬁed as both a critical structural
component of the binding pocket, and it contributes to ligand
binding. W183 is especially important as a constituent of the ‘ar-
omatic box’ that exists in all Cys-loop receptor binding sites (Beene
et al., 2002; Thompson et al., 2008b; Duffy et al., 2012). Other
residues (T179, H185, D189) are known to stabilise the binding site
structure via hydrogen bonds (Thompson et al., 2008b; Kesters
et al., 2013). It is therefore not surprising that all our loop B mu-
tations altered or abolished [3H]VUF10166 binding and we suggest
that T181 and W183 interact with VUF10166 while T179, H185 and
D189 have a structural role.
4.3. The role of loop C residues
F226 and Y234 are also constituents of the aromatic box and
mutations here alter or eliminate VUF10166 binding. F226A has no
effect on granisetron binding afﬁnity, indicating this residue is
more important for VUF10166 binding (Thompson et al., 2005). In
5HTBP Y234 (Y193) interacts with 5-HT and also contributes to a
conserved water network that stabilises the granisetron-bound
structure (Kesters et al., 2013); a conserved water network is also
seen at this location in many AChBP crystal structures and may beimportant in many Cys-loop receptors. E236C also abolished
VUF10166 binding, consistent with studies where substitutions
affect binding of both GR65630 and granisetron, as well as altering
the maximal current and EC50 of 5-HT responses (Schreiter et al.,
2003; Nyce et al., 2010). However E236 mutations may adversely
affect the correct assembly of the binding site rather than inter-
fering with speciﬁc ligand interactions as Nyce et al. (2010) and
Schreiter et al. (2003) showed that some E236mutant receptors are
trapped within the cell. As this hypothesis is supported by the lack
of interactions in the 5HTBP structure, we consider it unlikely that
E236 contributes to VUF10166 binding (Kesters et al., 2013).4.4. The role of loop D residues
W90 is another aromatic box residue that contributes to bind-
ing. In 5HTBP the equivalent residue (W53) is involved in van der
Waals interactions with granisetron and W90 may have a similar
role in binding VUF10166 (Spier and Lummis, 2000; Price and
Lummis, 2004; Thompson et al., 2005; Yan and White, 2005).
Substitutions at W90 decrease the afﬁnity of other potent 5-HT3
receptor-speciﬁc ligands such as curare, lerisetron and 5-HT (Yan
et al., 1999; Venkataraman et al., 2002a) R92 interacts with grani-
setron in 5HTBP (R55), and the effects of its substitution on the
afﬁnity of VUF10166, ondansetron, granisetron and MDL72222,
suggest an interaction with all of these ligands (Thompson et al.,
2005; Yan and White, 2005).4.5. The role of loop E residues
All of the mutations in loop E (Y141, Y143, R145, Q151, Y153)
caused signiﬁcant changes to [3H]VUF10166 binding. In the 5HTBP
crystal structure granisetron does not extend towards loop E, but
instead lies horizontally between loops B and D, similar to the
orientations of the closely related ligands tropisetron (2WNC) and
cocaine (2PGZ) in AChBP. In contrast, in 5HTBP 5-HT hydrogen
bonds with the backbone carbonyls of I104 (Y141 in 5-HT3) and I116
(Y153), and has hydrophobic interactions with M114 (Q151),
explaining why 5-HT activation is strongly affected by mutations at
these locations, but effects on granisetron are less apparent
(Venkataraman et al., 2002b; Price and Lummis, 2004; Thompson
et al., 2011; Kesters et al., 2013). Here the afﬁnity of VUF10166
was decreased 10-fold by Y153C and abolished by Y143C, indicating
Fig. 5. Radioligand binding at 5-HT3AB receptors. (a) Binding at 5-HT3AB receptors could not be well ﬁt with a standard one site model; deviation occurs at a radioligand con-
centration of ~3 nM (arrow). Inset competition binding of unlabelled VUF10166 with [3H]granisetron. (b) Dissociation was best ﬁt with a double exponential at 5-HT3AB receptors
(0.010 ± 0.003 min1 and 0.227 ± 0.056 min1, n ¼ 8). (c) Association was mono-exponential, but a plot of kobs against radioligand concentration. (d) revealed two components,
showing that it was rate-limited at higher concentrations. (e) The association of [3H]granisetron was best ﬁt with a mono-exponential function, but unlike [3H]VUF10166, the ﬁt of
kobs against the radioligand concentration was linear at across all concentrations, yielding the values for kon and koff in Table 1. (f) Consistent with this plot, dissociation of [3H]
granisetron was also best described by a single exponential function (koff ¼ (0.012 ± 0.002 min1, n ¼ 5)) that was not signiﬁcantly different to 5-HT3A receptors (p > 0.05, Student's
t-test).
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E residues. As VUF10166 is also a low efﬁcacy partial agonist at mM
concentrations, and must therefore induce the same structural
changes as 5-HT, it is likely it adopts an orientation that at least
partially mimics that of 5-HT.
4.6. The orientation of VUF10166 in the ligand binding pocket
Our results show that VUF10166 binding is affected by many of
the residues previously identiﬁed as important for binding 5-HT3receptor antagonists, while mutation of R58, I71, K112 and S114,
which are close to VUF10166 in models 1, 2 and 5, did not alter its
afﬁnity, suggesting that these models are less probable. Also in
model 1 the predicted ligand orientations do not extend towards
Loop E and yet residues herewere important for VUF10166 binding.
Similarly R145 is within 5 Å of VUF10166 in model 2, but our
mutagenesis data show that altering this residue has little effect on
binding afﬁnity. Model 3 seems unlikely as these poses are posi-
tioned closer to the complimentary face of the binding site, and do
not signiﬁcantly interact with key principal face residues such as
Fig. 6. Chemical structure of VUF10166 and its binding mode. (a) Three regions of the ligand are identiﬁed and are described in the text. Its protonation site, which is also its
tritiation site, is indicated. (bec) The volume occupied by the two main docked pose clusters in model 4. In (c) cationep interactions are possible with W183 (5.06 Å away) and Y234
(4.46 Å). VUF10166 is shown as a stick and wire mesh representation (white), with the residues mutated in this study colour coded similar to Fig. 4. (dee) Cartoons showing our
interpretation of the binding to heteromeric receptors. Below 3 nM, VUF10166 binds to a single population of binding sites at the AþA interface of both 5-HT3A and 5-HT3AB
receptors; consequently, at these concentrations both receptors share common values for kon and koff. At concentrations of VUF10166 > 3 nM, binding also occurs at a second AþB
binding site and allosterically inﬂuences the adjacent AþA site; therefore, additional rates are apparent and saturation binding is confounded by rates associated with multiple
binding sites and allosteric interactions. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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poses with only F226 distinguishing them; F226Cmutant receptors
had a 7-fold lower afﬁnity thanwild type receptors suggesting that
this residue is close enough to interfere with VUF10166 binding,
which would best ﬁt with model 4.
In previous work we presented a structure-activity study (SAR)
of VUF10166 analogues (Verheij et al., 2012; Thompson et al., 2013)
and the active analogues from these studies would ﬁt well into
model 4 in two distinct orientations (Fig. 6). These data showed
substitutions of the chlorine atom in VUF10166 (Fig. 6a, region 2)
are poorly tolerated, suggesting an important interaction at thislocation; in both poses in Fig. 6 the chlorine atom is closely located
to R92 and W90. In contrast, substitutions in regions 1 and 3 are
fairly well tolerated, providing that they are not too large; neither of
the poses in Fig. 6 are sterically restricted around these regions of
VUF10166. The poses also explain the importance of the charged N-
methylpiperazine nitrogen atom, as there are possible cationep
interactions with W183 and Y234 in one pose, with these residues
contributing to pep stacking of the quinoxaline ring in the other.
We therefore suggest that the docked poses in model 4 are most
consistent with the mutagenesis data described here and our pre-
viously published SAR. It is difﬁcult to predict whether the N-
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loop E, but the orientation in Fig. 6c is most reminiscent of vare-
nicline co-crystallised into AChBP (PDBID¼ 4AFG& 4AFT) and 5-HT
in 5HTBP (2YMD), both of which are agonists at 5-HT3 receptors
(Billen et al., 2012; Rucktooa et al., 2012). This similarity in orien-
tation may explain why VUF10166 also displays partial agonist
activity (Thompson et al., 2012). However, it should be stressed that
we must exercise caution when making these predictions as the
physiological relevance of these structures have not yet been fully
ascertained, for example three ligand molecules have been
observed in a single AChBP binding site, something we would not
have predicted (Brams et al., 2011; Stornaiuolo et al., 2013).
5. Conclusion
Our results show that VUF10166 interacts with several of the
core binding site residues found at the AþA interface and, com-
bined with homology modelling and ligand docking, we propose it
adopts an orientation similar to that of other 5-HT3 receptor ago-
nists in AChBP and 5HTBP crystal structures. At 5-HT3 receptors our
kinetic measurements are consistent with a single AþA binding
site, but at 5-HT3AB an additional fast component is seen. This is
consistent with the lower afﬁnity of VUF10166 for the 5-HT3AB
receptor and is likely to result from an allosteric effect that is
evident when the concentration of VUF10166 exceeds 3 nM (as
summarised in Fig. 6).
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